POSEIDON randomized phase II trial: Tamoxifen (TAM) plus taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2-metastatic breast cancer (MBC) von Oliveira, M, Baird, RD, Voorthuis, RAB, De Boo, L, van Rossum, AGJ, Cubells, L Garrigos, Munoz, S, Lopez-Garcia, D, Manich, C Saura, Schrier, M, Mandjes, I, Sikorska, K, Schot, M, Kateb, A, Mather, C, Beelen, K, Cortes, J, Caldas, C, Linn, SC

Volltext bestellen